Pacer Advisors Inc. Increases Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Pacer Advisors Inc. increased its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,730,771 shares of the biotechnology company’s stock after acquiring an additional 450,949 shares during the period. Pacer Advisors Inc. owned approximately 7.33% of Ironwood Pharmaceuticals worth $51,967,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in IRWD. Stonepine Capital Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 1,982.8% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after purchasing an additional 951,988 shares during the period. State Street Corp lifted its position in Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after buying an additional 677,024 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Ironwood Pharmaceuticals by 23.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock worth $7,846,000 after buying an additional 364,841 shares during the period. Robeco Institutional Asset Management B.V. increased its position in Ironwood Pharmaceuticals by 1,293.6% during the third quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company’s stock valued at $1,570,000 after acquiring an additional 353,624 shares during the last quarter. Finally, Wedge Capital Management L L P NC purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $1,297,000.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $3.80 on Tuesday. Ironwood Pharmaceuticals, Inc. has a 1-year low of $3.06 and a 1-year high of $15.70. The company has a 50-day moving average of $3.90 and a 200 day moving average of $4.54. The firm has a market capitalization of $608.11 million, a price-to-earnings ratio of -126.67 and a beta of 0.34.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. During the same quarter in the previous year, the business earned $0.12 EPS. The company’s quarterly revenue was down 19.4% compared to the same quarter last year. On average, equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the transaction, the chief financial officer now owns 309,572 shares of the company’s stock, valued at $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on IRWD shares. Craig Hallum lowered their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.